STARD5 作为肝细胞癌的潜在临床靶点。

STARD5 as a potential clinical target of hepatocellular carcinoma.

机构信息

Department of Histology and Embryology, School of Basic Medical Sciences, Tianjin Medical University, NO.22 Qixiangtai Road, Tianjin, China.

Department of Hepatology and Gastroenterology, The Third Central Clinical College of Tianjin Medical University, Tianjin, China.

出版信息

Med Oncol. 2022 Jul 19;39(10):156. doi: 10.1007/s12032-022-01750-8.

DOI:10.1007/s12032-022-01750-8

PMID:35852638

Abstract

To reveal whether STARD5 is a potential biomarker for diagnosis and prognosis of HCC. Using gene expression omnibus and the cancer genome atlas (TCGA) to screen differentially expressed genes in HCC and STARD5 was selected by LASSO algorithm. Then, we analyzed the association between STARD5 and clinical characteristics of HCC patients in TCGA and International Cancer Genome Consortium. Meanwhile, the mRNA and protein level of STARD5 was also verified by collecting 87 cases of HCC patients' liver tissues using qRT-PCR and WB. Next, we applied gene set enrichment analysis (GSEA) for pathways analysis of STARD5. Finally, TIMER1.0 and TISIDB were used to explore the correlation of STARD5 with immune cell infiltration. The expression of STARD5 was lower in HCC and negatively correlated with tumor grade (p < 0.05), while high expression of STARD5 suggested a better prognosis for HCC patients (p < 0.01) and it could be an independent prognostic predictor (p < 0.001). Meanwhile, STARD5 also had strong diagnostic accuracy for HCC patients. GSEA revealed that STARD5-related genes were mainly enriched in E2F targets, G2M checkpoint and KRAS signaling. The TIMER1.0 and TISIDB databases found a negative correlation between STARD5 and tumor immune infiltrating cells. STARD5 could be used as a potential target for HCC diagnosis and prognosis.

摘要

为了揭示 STARD5 是否是 HCC 诊断和预后的潜在生物标志物。使用基因表达综合数据库和癌症基因组图谱（TCGA）筛选 HCC 中的差异表达基因，并通过 LASSO 算法选择 STARD5。然后，我们在 TCGA 和国际癌症基因组联盟中分析了 STARD5 与 HCC 患者临床特征的相关性。同时，通过收集 87 例 HCC 患者的肝组织，使用 qRT-PCR 和 WB 验证了 STARD5 的 mRNA 和蛋白水平。接下来，我们应用基因集富集分析（GSEA）对 STARD5 的通路进行分析。最后，TIMER1.0 和 TISIDB 被用来探索 STARD5 与免疫细胞浸润的相关性。STARD5 在 HCC 中的表达较低，与肿瘤分级呈负相关（p<0.05），而 STARD5 的高表达提示 HCC 患者预后较好（p<0.01），且可作为独立预后预测因子（p<0.001）。同时，STARD5 对 HCC 患者也具有较强的诊断准确性。GSEA 显示，STARD5 相关基因主要富集在 E2F 靶标、G2M 检查点和 KRAS 信号通路中。TIMER1.0 和 TISIDB 数据库发现 STARD5 与肿瘤免疫浸润细胞呈负相关。STARD5 可作为 HCC 诊断和预后的潜在靶点。